Hyatt's Luxury Hotels Lead the Way in Q4 Growth
Since the article also highlights that they beat earnings expectations but missed on sales, you have a few ways to frame it:
Option 1: Focus on the Luxury Win
- Hyatt's Luxury Hotels Lead the Way in Q4 Growth
Hyatt Hotels Corporation shares are trading lower premarket on Thursday after the company reported mixed fourth-quarter FY25 results.
Sales of $1.789 billion, marginally missing the Street view of $1.802 billion.
Adjusted EBITDA was $292 million, up 14.6% Y/Y. Excluding 2024 asset sales, adjusted EBITDA rose 3.8% Y/Y.
Gross fees rose 4.5% Y/Y to $307 million in the quarter.
Hyatt Hotels reported adjusted profit of $1.33, exceeding the consensus of 45 cents.
As of Dec. 31, the company had $4.3 billion in total debt and $813 million in cash, cash equivalents and short-term investments.
Key Metrics
Hyatt’s comparable system-wide hotel revenue per available room (RevPAR) rose 4.0% year over year (Y/Y), and comparable system-wide all-inclusive resorts Net Package RevPAR increased 8.3% Y/Y in the quarter.
The company witnessed the highest RevPAR growth among Luxury and Upper Upscale chain scales.
In 2025, net rooms rose 7.3% and 6.7%, excluding acquisitions.
During the fourth quarter, the company opened 8,253 rooms.
At the end of the year, the pipeline of executed management or franchise contracts totaled 148,000 rooms, representing a 7% year-over-year increase.
Dividend
The company declared a 15-cent-per-share cash dividend for the first quarter of 2026, payable on March 12 to stockholders of record as of March 2, 2026.
Outlook
Hyatt expects 2026 comparable system-wide hotel RevPAR to rise 1.0% to 3.0% and Net rooms growth of 6.0% to 7.0% vs. 2025.
The company sees an adjusted EBITDA outlook of $1.155 billion- $1.205 billion and capital expenditure of about $135 million.
Price Action: Hyatt Hotels shares were down 1.23% at $166.55 at the time of publication on Thursday.
Photo: Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like


OKYO Pharma Announces Public Offering of Ordinary Shares

Electrovaya Reports Fiscal Year Q1 2026 Results

